Literature DB >> 23375727

Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery?

Michael J Worley1, Stephanie H Guseh, J Alejandro Rauh-Hain, Kristina A Williams, Michael G Muto, Colleen M Feltmate, Ross S Berkowitz, Neil S Horowitz.   

Abstract

OBJECTIVE: To compare primary debulking surgery (PDS) vs. neoadjuvant chemotherapy with interval debulking surgery (NACT-IDS) among elderly patients with ovarian/fallopian tube/primary peritoneal carcinoma.
METHODS: Medical records of patients ≥70 years old with epithelial ovarian/fallopian tube/primary peritoneal carcinoma between January 2000 and December 2010 were reviewed. Patients were separated by PDS or NACT-IDS. Preoperative characteristics, surgical procedures and postoperative and oncologic outcomes were compared. Surgical procedures were given a complexity score based on a previously published method.
RESULTS: Of 165 patients, 125 (75.8%) underwent PDS and 40 (24.2%) underwent NACT-IDS. Patients undergoing NACT-IDS were more likely to have a pleural effusion (without cytology) and stage 4 disease. Median CA-125 at diagnosis was greater for those undergoing NACT-IDS. The NACT-IDS group was associated with less intraoperative blood loss (250 vs. 400 mL, p=0.001), a greater chance of achieving no residual disease (40% vs. 16%, p=0.005) and a shorter hospital length of stay (LOS) (5 vs. 7 days, p<0.001). PFS (17 vs. 15 months, p=0.708) and OS (29 vs. 33 months, p=0.827) were similar between the two groups. Readmission rates within 30 days of surgery were greater in those undergoing PDS (17.6% vs. 2.5%, p=0.016). After readmission, the median hospital LOS was 6 days (range: 1-41).
CONCLUSIONS: Elderly patients undergoing PDS have similar oncologic outcomes when compared to patients undergoing NACT-IDS. The risk of readmission within 30 days of surgery is significantly greater among patients undergoing PDS.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23375727     DOI: 10.1016/j.ygyno.2013.01.012

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy.

Authors:  Seiya Sato; Hiroaki Itamochi
Journal:  Ther Adv Med Oncol       Date:  2014-11       Impact factor: 8.168

2.  Risk stratification and outcomes of women undergoing surgery for ovarian cancer.

Authors:  Sonali Patankar; William M Burke; June Y Hou; Ana I Tergas; Yongmei Huang; Cande V Ananth; Alfred I Neugut; Dawn L Hershman; Jason D Wright
Journal:  Gynecol Oncol       Date:  2015-05-11       Impact factor: 5.482

3.  Surgical readmission and survival in women with ovarian cancer: Are short-term quality metrics incentivizing decreased long-term survival?

Authors:  Emma L Barber; Emma C Rossi; Paola A Gehrig
Journal:  Gynecol Oncol       Date:  2017-09-21       Impact factor: 5.482

Review 4.  Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction.

Authors:  Mackenzie Cummings; Olivia Nicolais; Mark Shahin
Journal:  Diagnostics (Basel)       Date:  2022-04-14

5.  The role of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer: a systematic review and meta-analysis of randomized controlled trials and observational studies.

Authors:  Meng Qin; Ying Jin; Li Ma; Yan-Yan Zhang; Ling-Ya Pan
Journal:  Oncotarget       Date:  2017-12-27

6.  Efficacy and safety of neoadjuvant chemotherapy versus primary debulking surgery in patients with ovarian cancer: a meta-analysis.

Authors:  Xiaofeng Lv; Shihong Cui; Xiao'an Zhang; Chenchen Ren
Journal:  J Gynecol Oncol       Date:  2019-10-21       Impact factor: 4.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.